Form 4: Lexeo Therapeutics CEO Richard Townsend Exercises Options and Sells Shares
SEC Form 4 Filing
Lexeo Therapeutics CEO Richard Townsend executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Richard Nolan Townsend, CEO of Lexeo Therapeutics, exercised options to purchase 5,000 shares of common stock at a price of $2.33 on June 10, 2024.
- He then sold 2,962 shares at a weighted average price of $17.29 and 2,038 shares at a weighted average price of $18.18 on the same day.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 19, 2023.
- Following these transactions, Townsend directly owns 170,695 shares of Lexeo Therapeutics, including 43,750 restricted stock units (RSUs).
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating routine transactions. The sentiment is neutral as it simply reports facts.
Industry Context
Executive stock transactions are common and often pre-planned to comply with insider trading regulations. The use of a 10b5-1 plan indicates that these sales were scheduled in advance.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the CEO's stock sales, but the existence of a 10b5-1 plan suggests these were pre-planned and not based on current insider knowledge.
Key Dates
| Date | Description |
|---|---|
| December 19, 2023 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| June 10, 2024 | Date of stock option exercise and share sales |
| June 12, 2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.